Cargando…
Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer
PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glu...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927598/ https://www.ncbi.nlm.nih.gov/pubmed/26630973 http://dx.doi.org/10.1007/s11307-015-0916-7 |
_version_ | 1782440284199583744 |
---|---|
author | Alberini, Jean-Louis Boisgard, Raphaël Guillermet, Stéphanie Siquier, Karine Jego, Benoît Thézé, Benoît Urien, Saik Rezaï, Keyvan Menet, Emmanuelle Maroy, Renaud Dollé, Frédéric Kühnast, Bertrand Tavitian, Bertrand |
author_facet | Alberini, Jean-Louis Boisgard, Raphaël Guillermet, Stéphanie Siquier, Karine Jego, Benoît Thézé, Benoît Urien, Saik Rezaï, Keyvan Menet, Emmanuelle Maroy, Renaud Dollé, Frédéric Kühnast, Bertrand Tavitian, Bertrand |
author_sort | Alberini, Jean-Louis |
collection | PubMed |
description | PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), single photon emission tomography (SPECT) with [(99m)Tc]TcO(4) ([(99m)Tc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [(18)F]FDG and [(99m)Tc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed. RESULTS: All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [(99m)Tc]TEC and [(18)F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [(18)F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [(18)F]FDG and [(99m)Tc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week(−1) in untreated, doxorubicin, and docetaxel groups, respectively. CONCLUSIONS: Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [(18)F]FDG-PET and [(99m)Tc]TEC SPECT monitor tumor response to chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-015-0916-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4927598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-49275982016-07-13 Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer Alberini, Jean-Louis Boisgard, Raphaël Guillermet, Stéphanie Siquier, Karine Jego, Benoît Thézé, Benoît Urien, Saik Rezaï, Keyvan Menet, Emmanuelle Maroy, Renaud Dollé, Frédéric Kühnast, Bertrand Tavitian, Bertrand Mol Imaging Biol Research Article PURPOSE: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy. PROCEDURES: Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-d-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), single photon emission tomography (SPECT) with [(99m)Tc]TcO(4) ([(99m)Tc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [(18)F]FDG and [(99m)Tc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed. RESULTS: All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [(99m)Tc]TEC and [(18)F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [(18)F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [(18)F]FDG and [(99m)Tc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week(−1) in untreated, doxorubicin, and docetaxel groups, respectively. CONCLUSIONS: Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [(18)F]FDG-PET and [(99m)Tc]TEC SPECT monitor tumor response to chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11307-015-0916-7) contains supplementary material, which is available to authorized users. Springer US 2015-12-02 2016 /pmc/articles/PMC4927598/ /pubmed/26630973 http://dx.doi.org/10.1007/s11307-015-0916-7 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article Alberini, Jean-Louis Boisgard, Raphaël Guillermet, Stéphanie Siquier, Karine Jego, Benoît Thézé, Benoît Urien, Saik Rezaï, Keyvan Menet, Emmanuelle Maroy, Renaud Dollé, Frédéric Kühnast, Bertrand Tavitian, Bertrand Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title_full | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title_fullStr | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title_full_unstemmed | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title_short | Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer |
title_sort | multimodal in vivo imaging of tumorigenesis and response to chemotherapy in a transgenic mouse model of mammary cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927598/ https://www.ncbi.nlm.nih.gov/pubmed/26630973 http://dx.doi.org/10.1007/s11307-015-0916-7 |
work_keys_str_mv | AT alberinijeanlouis multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT boisgardraphael multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT guillermetstephanie multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT siquierkarine multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT jegobenoit multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT thezebenoit multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT uriensaik multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT rezaikeyvan multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT menetemmanuelle multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT maroyrenaud multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT dollefrederic multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT kuhnastbertrand multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer AT tavitianbertrand multimodalinvivoimagingoftumorigenesisandresponsetochemotherapyinatransgenicmousemodelofmammarycancer |